{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T16:07:25Z","timestamp":1746202045022,"version":"3.37.3"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,10,24]],"date-time":"2018-10-24T00:00:00Z","timestamp":1540339200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1007\/s10549-018-5017-2","type":"journal-article","created":{"date-parts":[[2018,10,24]],"date-time":"2018-10-24T07:15:01Z","timestamp":1540365301000},"page":"397-406","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Oral etoposide in heavily pre-treated metastatic breast cancer: results from the ESME cohort and comparison with other chemotherapy regimens"],"prefix":"10.1007","volume":"173","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5515-9180","authenticated-orcid":false,"given":"Luc","family":"Cabel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthieu","family":"Carton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bianca","family":"Cheaib","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Yves","family":"Pierga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florence","family":"Dalenc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Audrey","family":"Mailliez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christelle","family":"Levy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Jacot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Debled","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianne","family":"Leheurteur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Desmoulins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Lefeuvre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Gon\u00e7alves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lionel","family":"Uwer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Marc","family":"Ferrero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Christophe","family":"Eymard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thierry","family":"Petit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Ange","family":"Mouret-Reynier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Genevi\u00e8ve","family":"Perrocheau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irwin","family":"Piot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"P\u00e9rol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ga\u00ebtane","family":"Simon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florence","family":"Lerebours","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,10,24]]},"reference":[{"key":"5017_CR1","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1093\/annonc\/mdy192","volume":"29","author":"F Cardoso","year":"2018","unstructured":"Cardoso F, Senkus E, Costa A et al (2018) 4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)\u2020. Ann Oncol 29:1634\u20131657. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdy192","journal-title":"Ann Oncol"},{"key":"5017_CR2","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3322\/caac.21262","volume":"65","author":"LA Torre","year":"2015","unstructured":"Torre LA, Bray F, Siegel RL et al (2015) Global cancer statistics, 2012. CA Cancer J Clin 65:87\u2013108. \n                    https:\/\/doi.org\/10.3322\/caac.21262","journal-title":"CA Cancer J Clin"},{"key":"5017_CR3","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1097\/00000421-199810000-00004","volume":"21","author":"L Pusztai","year":"1998","unstructured":"Pusztai L, Walters RS, Valero V et al (1998) Daily oral etoposide in patients with heavily pretreated metastatic breast cancer. Am J Clin Oncol 21:442\u2013446","journal-title":"Am J Clin Oncol"},{"key":"5017_CR4","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.1002\/1097-0142(19951215)76:12<2485::AID-CNCR2820761212>3.0.CO;2-J","volume":"76","author":"DM Atienza","year":"1995","unstructured":"Atienza DM, Vogel CL, Trock B, Swain SM (1995) Phase II study of oral etoposide for patients with advanced breast cancer. Cancer 76:2485\u20132490","journal-title":"Cancer"},{"key":"5017_CR5","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1097\/00001813-199607000-00009","volume":"7","author":"ZB Neskovi\u0107-Konstantinovi\u0107","year":"1996","unstructured":"Neskovi\u0107-Konstantinovi\u0107 ZB, Bosnjak SM, Radulovi\u0107 SS, Mitrovi\u0107 LB (1996) Daily oral etoposide in metastatic breast cancer. Anticancer Drugs 7:543\u2013547","journal-title":"Anticancer Drugs"},{"key":"5017_CR6","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1200\/JCO.1994.12.5.986","volume":"12","author":"M Mart\u00edn","year":"1994","unstructured":"Mart\u00edn M, Lluch A, Casado A et al (1994) Clinical activity of chronic oral etoposide in previously treated metastatic breast cancer. J Clin Oncol 12:986\u2013991. \n                    https:\/\/doi.org\/10.1200\/JCO.1994.12.5.986","journal-title":"J Clin Oncol"},{"key":"5017_CR7","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1111\/tbj.12398","volume":"21","author":"G Valabrega","year":"2015","unstructured":"Valabrega G, Berrino G, Milani A et al (2015) A retrospective analysis of the activity and safety of oral Etoposide in heavily pretreated metastatic breast cancer patients. Breast J 21:241\u2013245. \n                    https:\/\/doi.org\/10.1111\/tbj.12398","journal-title":"Breast J"},{"key":"5017_CR8","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1097\/00001813-200103000-00004","volume":"12","author":"M Jagodic","year":"2001","unstructured":"Jagodic M, Cufer T, Zakotnik B, Cervek J (2001) Selection of candidates for oral etoposide salvage chemotherapy in heavily pretreated breast cancer patients. Anticancer Drugs 12:199\u2013204","journal-title":"Anticancer Drugs"},{"key":"5017_CR9","doi-asserted-by":"publisher","first-page":"10","DOI":"10.5152\/ejbh.2017.3563","volume":"14","author":"IA Voutsadakis","year":"2018","unstructured":"Voutsadakis IA (2018) A systematic review and pooled analysis of studies of oral etoposide in metastatic breast cancer. Eur J Breast Health 14:10\u201316. \n                    https:\/\/doi.org\/10.5152\/ejbh.2017.3563","journal-title":"Eur J Breast Health"},{"key":"5017_CR10","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1093\/annonc\/mdw260","volume":"27","author":"S Delaloge","year":"2016","unstructured":"Delaloge S, P\u00e9rol D, Courtinard C et al (2016) Paclitaxel plus bevacizumab or paclitaxel as first-line treatment for HER2-negative metastatic breast cancer in a multicenter national observational study. Ann Oncol 27:1725\u20131732. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdw260","journal-title":"Ann Oncol"},{"key":"5017_CR11","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ejca.2018.03.015","volume":"96","author":"E Gobbini","year":"2018","unstructured":"Gobbini E, Ezzalfani M, Dieras V et al (2018) Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort. Eur J Cancer 96:17\u201324. \n                    https:\/\/doi.org\/10.1016\/j.ejca.2018.03.015","journal-title":"Eur J Cancer"},{"key":"5017_CR12","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.ejca.2018.03.013","volume":"95","author":"E Jacquet","year":"2018","unstructured":"Jacquet E, Lardy-Cl\u00e9aud A, Pistilli B et al (2018) Endocrine therapy or chemotherapy as first-line therapy in hormone receptor-positive HER2-negative metastatic breast cancer patients. Eur J Cancer 95:93\u2013101. \n                    https:\/\/doi.org\/10.1016\/j.ejca.2018.03.013","journal-title":"Eur J Cancer"},{"key":"5017_CR13","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1002\/sim.3150","volume":"27","author":"PC Austin","year":"2008","unstructured":"Austin PC (2008) A critical appraisal of propensity-score matching in the medical literature between 1996 and 2003. Stat Med 27:2037\u20132049. \n                    https:\/\/doi.org\/10.1002\/sim.3150","journal-title":"Stat Med"},{"key":"5017_CR14","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1111\/j.0006-341X.2000.00118.x","volume":"56","author":"K Ming","year":"2000","unstructured":"Ming K, Rosenbaum PR (2000) Substantial gains in bias reduction from matching with a variable number of controls. Biometrics 56:118\u2013124","journal-title":"Biometrics"},{"unstructured":"R Core Team (2017) R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna","key":"5017_CR15"},{"key":"5017_CR16","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.breast.2018.01.006","volume":"38","author":"G Giannone","year":"2018","unstructured":"Giannone G, Milani A, Ghisoni E et al (2018) Oral etoposide in heavily pre-treated metastatic breast cancer: a retrospective series. Breast 38:160\u2013164. \n                    https:\/\/doi.org\/10.1016\/j.breast.2018.01.006","journal-title":"Breast"},{"key":"5017_CR17","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1097\/00000421-200006000-00010","volume":"23","author":"T Saphner","year":"2000","unstructured":"Saphner T, Weller EA, Tormey DC et al (2000) 21-day oral etoposide for metastatic breast cancer: a phase II study and review of the literature. Am J Clin Oncol 23:258\u2013262","journal-title":"Am J Clin Oncol"},{"key":"5017_CR18","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/BF00686513","volume":"33","author":"H Palombo","year":"1994","unstructured":"Palombo H, Estap\u00e9 J, Vi\u00f1olas N et al (1994) Chronic oral etoposide in advanced breast cancer. Cancer Chemother Pharmacol 33:527\u2013529","journal-title":"Cancer Chemother Pharmacol"},{"key":"5017_CR19","doi-asserted-by":"publisher","first-page":"e774","DOI":"10.1097\/MD.0000000000000774","volume":"94","author":"P Yuan","year":"2015","unstructured":"Yuan P, Di L, Zhang X et al (2015) Efficacy of oral etoposide in pretreated metastatic breast cancer: a multicenter phase 2 study. Medicine (Baltimore) 94:e774. \n                    https:\/\/doi.org\/10.1097\/MD.0000000000000774","journal-title":"Medicine (Baltimore)"},{"key":"5017_CR20","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/S0140-6736(11)60070-6","volume":"377","author":"J Cortes","year":"2011","unstructured":"Cortes J, O\u2019Shaughnessy J, Loesch D et al (2011) Eribulin monotherapy versus treatment of physician\u2019s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet 377:914\u2013923. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(11)60070-6","journal-title":"Lancet"},{"key":"5017_CR21","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1038\/nrclinonc.2015.131","volume":"12","author":"E Munzone","year":"2015","unstructured":"Munzone E, Colleoni M (2015) Clinical overview of metronomic chemotherapy in breast cancer. Nat Rev Clin Oncol 12:631\u2013644. \n                    https:\/\/doi.org\/10.1038\/nrclinonc.2015.131","journal-title":"Nat Rev Clin Oncol"},{"key":"5017_CR22","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.canlet.2016.12.019","volume":"400","author":"ME Cazzaniga","year":"2017","unstructured":"Cazzaniga ME, Dionisio MR, Riva F (2017) Metronomic chemotherapy for advanced breast cancer patients. Cancer Lett 400:252\u2013258. \n                    https:\/\/doi.org\/10.1016\/j.canlet.2016.12.019","journal-title":"Cancer Lett"},{"key":"5017_CR23","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/S2213-0896(16)06001-1","volume":"6","author":"F Cardoso","year":"2016","unstructured":"Cardoso F, Colleoni M, Di Leo A et al (2016) Oral chemotherapy in advanced breast cancer: expert perspectives on its role in clinical practice. Cancer Treat Commun 6:S1\u2013S10. \n                    https:\/\/doi.org\/10.1016\/S2213-0896(16)06001-1","journal-title":"Cancer Treat Commun"},{"key":"5017_CR24","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1177\/1758834013508197","volume":"5","author":"R Palumbo","year":"2013","unstructured":"Palumbo R, Sottotetti F, Riccardi A et al (2013) Which patients with metastatic breast cancer benefit from subsequent lines of treatment? An update for clinicians. Ther Adv Med Oncol 5:334\u2013350. \n                    https:\/\/doi.org\/10.1177\/1758834013508197","journal-title":"Ther Adv Med Oncol"},{"key":"5017_CR25","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.breast.2011.07.010","volume":"20","author":"E Planchat","year":"2011","unstructured":"Planchat E, Abrial C, Thivat E et al (2011) Late lines of treatment benefit survival in metastatic breast cancer in current practice? Breast 20:574\u2013578. \n                    https:\/\/doi.org\/10.1016\/j.breast.2011.07.010","journal-title":"Breast"},{"key":"5017_CR26","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1080\/07357900802290580","volume":"27","author":"O Tacca","year":"2009","unstructured":"Tacca O, LeHeurteur M, Durando X et al (2009) Metastatic breast cancer: overall survival related to successive chemotherapies. What do we gain after the third line? Cancer Invest 27:81\u201385. \n                    https:\/\/doi.org\/10.1080\/07357900802290580","journal-title":"Cancer Invest"},{"key":"5017_CR27","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.2147\/OTT.S63302","volume":"7","author":"C Beauchemin","year":"2014","unstructured":"Beauchemin C, Cooper D, Lapierre M-\u00c8 et al (2014) Progression-free survival as a potential surrogate for overall survival in metastatic breast cancer. Oncol Targets Ther 7:1101\u20131110. \n                    https:\/\/doi.org\/10.2147\/OTT.S63302","journal-title":"Oncol Targets Ther"},{"key":"5017_CR28","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1007\/s10549-015-3643-5","volume":"154","author":"G Adunlin","year":"2015","unstructured":"Adunlin G, Cyrus JWW, Dranitsaris G (2015) Correlation between progression-free survival and overall survival in metastatic breast cancer patients receiving anthracyclines, taxanes, or targeted therapies: a trial-level meta-analysis. Breast Cancer Res Treat 154:591\u2013608. \n                    https:\/\/doi.org\/10.1007\/s10549-015-3643-5","journal-title":"Breast Cancer Res Treat"},{"key":"5017_CR29","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.bulcan.2016.01.002","volume":"103","author":"L Liu","year":"2016","unstructured":"Liu L, Chen F, Zhao J, Yu H (2016) Correlation between overall survival and other endpoints in metastatic breast cancer with second- or third-line chemotherapy: Literature-based analysis of 24 randomized trials. Bull Cancer 103:336\u2013344. \n                    https:\/\/doi.org\/10.1016\/j.bulcan.2016.01.002","journal-title":"Bull Cancer"},{"key":"5017_CR30","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1200\/JCO.2007.10.8407","volume":"26","author":"T Burzykowski","year":"2008","unstructured":"Burzykowski T, Buyse M, Piccart-Gebhart MJ et al (2008) Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer. J Clin Oncol 26:1987\u20131992. \n                    https:\/\/doi.org\/10.1200\/JCO.2007.10.8407","journal-title":"J Clin Oncol"},{"key":"5017_CR31","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1038\/sj.bjc.6604759","volume":"99","author":"B Sherrill","year":"2008","unstructured":"Sherrill B, Amonkar M, Wu Y et al (2008) Relationship between effects on time-to-disease progression and overall survival in studies of metastatic breast cancer. Br J Cancer 99:1572\u20131578. \n                    https:\/\/doi.org\/10.1038\/sj.bjc.6604759","journal-title":"Br J Cancer"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-018-5017-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-018-5017-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-018-5017-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,23]],"date-time":"2019-10-23T20:09:09Z","timestamp":1571861349000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-018-5017-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,24]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["5017"],"URL":"https:\/\/doi.org\/10.1007\/s10549-018-5017-2","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"type":"print","value":"0167-6806"},{"type":"electronic","value":"1573-7217"}],"subject":[],"published":{"date-parts":[[2018,10,24]]},"assertion":[{"value":"28 September 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The present analysis was approved by an independent ethics committee (Comit\u00e9 De Protection Des Personnes Sud-Est II- 2015-79). No formal dedicated informed consent was required but all patients had approved the re-use of their electronically recorded data. In compliance with French regulations, the ESME MBC database was authorized by the French data protection authority (Authorization No. 1704113).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}